← Evidence map

ArticleUrologie (Heidelberg, Germany)2025

[Next generation sequencing (NGS)-based molecular panel analysis for metastatic prostate cancer: how often can we detect druggable mutations? : NGS for metastatic adenocarcinoma of the prostate].

Olivia Steenbock et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

[Next generation sequencing (NGS)-based molecular panel analysis for metastatic prostate cancer: how often can we detect druggable mutations? : NGS for metastatic adenocarcinoma of the prostate]. | OpenQuestion